iBio, Inc. (NYSE:IBIO) CFO Felipe Duran Acquires 9,191 Shares of Stock

iBio, Inc. (NYSE:IBIO) CFO Felipe Duran acquired 9,191 shares of iBio stock in a transaction dated Friday, January 10th. The shares were bought at an average cost of $2.72 per share, with a total value of $24,999.52. Following the completion of the purchase, the chief financial officer now owns 11,139 shares in the company, valued at approximately $30,298.08. This represents a 471.82 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

iBio Price Performance

Shares of iBio stock opened at $2.48 on Tuesday. iBio, Inc. has a 12-month low of $1.02 and a 12-month high of $4.98. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.04. The stock’s fifty day moving average is $2.51 and its 200-day moving average is $2.29.

iBio (NYSE:IBIO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.46). Equities research analysts predict that iBio, Inc. will post -1.74 EPS for the current fiscal year.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.